Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Hertz

Showing results (351-360 of 368) with videos related to

Pageof 37
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|November 7, 2023
Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221Ciao-Sin Chen, Gary Zirpoli, William E Barlow, et al.
Cancer|November 25, 2014
Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance)Jai N Patel, Chen Jiang, Daniel L Hertz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2020
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline UpdateCharles L Loprinzi, Christina Lacchetti, Jonathan Bleeker, et al.
Journal of Medical Genetics|August 30, 2008
Refinement of cortical dysgeneses spectrum associated with TUBA1A mutationsN Bahi-Buisson, K Poirier, N Boddaert, et al.
JAMA Network Open|April 10, 2026
Risk Prediction Model for Taxane-Induced Peripheral Neuropathy in Early-Stage CancerMeghna S Trivedi, Joseph M Unger, N Lynn Henry, et al.
Clinical Pharmacology and Therapeutics|June 5, 2025
Progress in Pharmacogenomics Implementation in the United States: Barrier Erosion and Remaining ChallengesD Max Smith, Michael P Douglas, Christina L Aquilante, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 1, 2019
Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overviewAlexandre Chan, Daniel L Hertz, Manuel Morales, et al.
The Pharmacogenomics Journal|March 4, 2024
Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance)Jai N Patel, Chen Jiang, Kouros Owzar, et al.
Pharmacogenomics|August 24, 2023
Effects of <i>CYP3A4</i> and <i>CYP2C9</i> genotype on systemic anastrozole and fulvestrant concentrations in SWOG S0226Delaney V Rutherford, Sarah Medley, Nicholas C Henderson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2017
Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset CancerM Eileen Dolan, Omar El Charif, Heather E Wheeler, et al.
Pageof 37

Showing results (351-360 of 368) with videos related to

Sort By:
Pageof 37
Journal of the National Comprehensive Cancer Network : JNCCN|November 7, 2023
Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221Ciao-Sin Chen, Gary Zirpoli, William E Barlow, et al.
Cancer|November 25, 2014
Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance)Jai N Patel, Chen Jiang, Daniel L Hertz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2020
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline UpdateCharles L Loprinzi, Christina Lacchetti, Jonathan Bleeker, et al.
Journal of Medical Genetics|August 30, 2008
Refinement of cortical dysgeneses spectrum associated with TUBA1A mutationsN Bahi-Buisson, K Poirier, N Boddaert, et al.
JAMA Network Open|April 10, 2026
Risk Prediction Model for Taxane-Induced Peripheral Neuropathy in Early-Stage CancerMeghna S Trivedi, Joseph M Unger, N Lynn Henry, et al.
Clinical Pharmacology and Therapeutics|June 5, 2025
Progress in Pharmacogenomics Implementation in the United States: Barrier Erosion and Remaining ChallengesD Max Smith, Michael P Douglas, Christina L Aquilante, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 1, 2019
Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overviewAlexandre Chan, Daniel L Hertz, Manuel Morales, et al.
The Pharmacogenomics Journal|March 4, 2024
Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance)Jai N Patel, Chen Jiang, Kouros Owzar, et al.
Pharmacogenomics|August 24, 2023
Effects of <i>CYP3A4</i> and <i>CYP2C9</i> genotype on systemic anastrozole and fulvestrant concentrations in SWOG S0226Delaney V Rutherford, Sarah Medley, Nicholas C Henderson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2017
Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset CancerM Eileen Dolan, Omar El Charif, Heather E Wheeler, et al.
Pageof 37